Magnitude Biosciences

Executive Summary

Magnitude Biosciences is a UK-based contract research organization (CRO) that leverages the C. elegans nematode model for whole-organism, high-throughput screening. Its proprietary WormGazer™ imaging and VivoScan™ platform enable cost-effective, scalable screening and mode-of-action studies for pharma, biotech, and nutraceutical clients. Focusing on ageing, neurodegeneration, metabolic health, and toxicity, the company offers a unique in vivo alternative to traditional cell-based assays, reducing costs and accelerating preclinical timelines. Founded in 2016 and headquartered in Manchester, Magnitude targets the growing demand for phenotypic screening in drug discovery, particularly for age-related and metabolic diseases where complex organismal biology is critical. While the company has remained private and low-profile, its specialized CRO services position it as a key partner for early-stage drug development and nutraceutical efficacy testing. With no disclosed funding rounds, the firm likely operates on a service-revenue model, gradually building a client base and expanding its assay portfolio. The competitive landscape includes other CROs using zebrafish or rodents, but Magnitude’s focus on C. elegans offers a distinct cost and throughput advantage, especially for large libraries. Challenges include market education on the relevance of C. elegans for human disease and competition from more established model organisms.

Upcoming Catalysts (preview)

• Q3 2026Expansion of assay services for neurodegeneration and metabolic health70% success
• TBDPartnership with a top-20 pharma company for ageing research40% success